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INTRODUCTION
Colonic  drug  delivery  (CDD)  is  intended  for  the 
local treatment of ulcerative colitis, inflammatory 
bowel diseases and can potentially be used for colon 
cancer or the systemic administration of drugs that 
are adversely affected by the upper gastro-intestinal 
(GI) tract (1). CDD have advantages of minimum 
systemic absorption, administration of lower drug 
doses,  high  concentrations  of  drug  in  the  distal 
small  intestine  and  the  colon  without  systemic 
exposure and toxicity. There has been considerable 
investigation for the design of CDD systems and 
targeting has been achieved by different methods. 
Delivery systems controlling release of drug only in 
the colon has been reported (2). 
Mesalazine  (MZ),  an  anti-inflammatory  drug, 
prevents  development  of  colorectal  cancer  and 
ulcerative colitis (3,4). MZ (t1/2: 0.6 to 1.4 hrs) is 
rapidly absorbed from the small intestine and there is 
a little localization in the colon relative to the small 
intestine (5). Therefore, to increase its localization 
in the colon; development of a polysaccharide based 
delivery system is required. The rationale for the 
development  of  a  polysaccharide  based  delivery 
system for colon is the ability of the colonic microfolra 
to  degrade  various  types  of  polysaccharides  that 
escape small bowel digestion (6). Pectins are naturally 
occurring biodegradable polysaccharides consisting 
of  linear  chain  of  1-4  linked  α-D-galacturonic 
acid residues with varying degrees of methyl ester 
substituents (7). They are broken down by various 
microbial sources including human colonic bacteria 
and may therefore be utilized as CDD systems if 
their solubility are reduced. Major efforts have been 
focused should be deleted for pectin derivatives (8) 
and use of calcium and zinc salts of pectin because 
binding of calcium and zinc induces non-covalent 
associations of carbohydrate chains through “egg-
box” complexes (9) which are more water resistant, 
while still enzymatically degradable. In this study 
the  effects  of  different  formulation  variables  upon 
the characteristics of pectinate microparticles (MPs) 
prepared by ionotropic gelation technique for colonic 
delivery of mesalazine was investigated.
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Background and the purpose of the study: Pectin derivatives have been utilized for colonic 
drug delivery (CDD). In this study the effects of different formulation variables upon the 
characteristics of pectinate microparticles (MPs) prepared by ionotropic gelation technique for 
colonic delivery of mesalazine was investigated. 
Methods: In-vitro drug release of MPs was studied using USP XXIV dissolution apparatus type 
I, in different fluids e.g. simulated gastric fluid (SGF: pH 1.2), simulated intestinal fluid (SIF: 
pH 7.4), and simulated colonic fluid (SCF: pH 6.8) of volume 900 ml, at 100 rpm maintained at 
37 ± 0.2 °C. This study was also performed in the presence of 4% w/v rat caecal content (RCC) 
using phosphate buffer saline (pH 6.8) as SCF. Gamma scintigraphy study was performed on 
New Zealand rabbit animal model using 99m Tc.
Results: The results showed that maximum entrapment of mesalazine (86.1 ± 1.7 %) and strength 
of gel network zinc pectinate gel microparticles (ZPGD2) was achieved in cross-linking solution 
of pH 1.6. Batch of ZPGD2 showed least swelling ratio and drug release. In RCC medium the 
t50% value of CPG-MPs was 3-4 folds greater than ZPG-MPs. Scintigram showed the residence 
of ZPG-MPs (filled in enteric coated capsule) in colon more than 9 hrs and delivery of almost 
all the drug loading dose in colon.
Major conclusion: The results of this study suggest the designed formulation of ZPG-MPs has 
the potential to serve as a colonic drug delivery system.
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cross-linking solution for 6 to 24 hrs. The MPs 
were separated by filtration, washed three times 
with deionized water and dried at 37 ˚C for 48 hrs 
in a drying room. Different variables were investigated 
and are summarised in table 1.
Determination of size distribution of MPs
Particle  size  and  size  distribution  of  different 
formulations  of  zinc  pectinate  gel  microparticles 
(ZPG-MPs) and calcium pectinate gel microparticles 
(CPG-MPs)  were  measured  using  an  optical 
microscope with calibrated ocular micrometer and 
the mean particle size was calculated by measurement 
of 300 particles of each formulation. 
Entrapment efficiency (EE) 
A weighed amount of MZ loaded MPs was suspended 
in  phosphate  buffer  (pH  6.8)  and  magnetically 
stirred at 200 rpm for 24 hrs to promote swelling and 
breakup of the cross-linked structure. This solution 
was vacuum filtered through a 0.45 µm membrane 
filter  (Millipore  Corp,  MA)  and  the  absorbance 
of the resulting solution was measured at 330 nm 
using UV-spectrophotometer (Systronic, Japan) to 
determine the entrapment efficiency.
Swellability of MPs
MPs  (100  mg)  were  placed  in  little  excess  of 
simulated  colonic  fluid  (SCF:  KH2PO4/NaOH 
buffer, pH 6.8) and allowed to swell for the required 
period of time using the dissolution apparatus with 
the dissolution basket assembly at 100 rpm and 
37 ± 0.2 °C. The MPs were periodically removed 
at pre-determined intervals, blotted with filter paper 
and  their  changes  in  weight  (after  correction  for 
drug loss) were measured during the swelling until 
equilibrium was attained. Finally, the weight of the 
swollen MPs was recorded and the swelling ratio 
(SR) was then calculated  from the formula:
SR = [(Wf − Wi)/Wi] 
MATERIAl  AND  METhODS
Materials
Mesalazine, Pure pectin, and SnCl2 were purchased 
from HiMedia Laboratory Pvt. Ltd, Mumbai (India). 
Amidated low methoxy (LM) pectin (29.7% degree 
of  esterification  and  13.3%  degree  of  amidation)
were prepared in author’s laboratory by the reported 
method (10). Zn(CH3COO)2  and CaCl2 dihydrate 
were purchased from Central Drug House Pvt. Ltd, 
New Delhi (India). 99m Tc as pertechnetate (99mTcO-
4) 
for  radiolabeling  of  MPs  was  obtained  from  the 
Nuclear  Medicine  Department,  Jawaharlal  Nehru 
Cancer  Hospital  and  Research  Center,  Bhopal 
(India). All should be deleted other chemicals and 
solvents were of analytical reagent grade. 
The  in  vivo  study  was  performed  by  a  protocol 
approved  by  the  Committee  for  the  Purpose  of 
Control and Supervision of Experiments on Animals, 
Ministry  of  Social  Justice  and  Empowerment, 
Government  of  India.  Animal  Ethical  committee 
of Jawaharlal Nehru Cancer Hospital and Research 
Centre, Bhopal (India) granted permission for the 
Hospital and Research Centre, Bhopal (India).
Preparation of MPs
The  ionotropic  gelation  technique,  (11-13)  was 
used with slight modifications. Aqueous dispersion 
of  LM-pectin  (2%  or  4%  w/v)  was  prepared  by 
overnight  agitation.  A  specified  amount  of  MZ 
(1% w/v) was dispersed into the agitated polymer 
dispersion until a uniform dispersion was obtained. 
This  homogenous,  and  bubble-free  dispersion 
was  dropped  through  a  disposable  syringe  (0.6 
mm  inner  diameter  of  nozzle)  at  an  average 
rate of 1 ml/min, into 50 ml solution of cross-
linking  agent  (0.1  M  of  Zn(CH3COO)2 or  0.15 
M of CaCl2 dihydrate) agitated at 150 rpm. The 
falling distance was 5 cm. The pH of this solution 
was adjusted at 1.6, 3.8 and 6.1 by 1 N HCl. The 
formed MPs gelles were allowed to stand in the 
Formulation
code
lM-Pectin Conc. 
(% w/v)
Zn(Ch3COO)2
(0.1 M) ph
CaCl2
(0.15 M) ph
Cross-linking
time (hrs)
ZPGA1 2 1.6 ― 6
ZPGA2 4 1.6 ― 6
ZPGB1 2 3.8 ― 6
ZPGB2 4 3.8 ― 6
ZPGC1 2 6.1 ― 6
ZPGC2 4 6.1 ― 6
ZPGD1 4 1.6 ― 12
ZPGD2 4 1.6 ― 24
CPG 4 ― 1.6 24
Table 1. Various formulations of microparticles.
*ZPG and CPG indicate zinc pectinate gel microparticles and calcium pectinate gel microparticles respectively
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where Wi is the initial weight of the MPs and Wf is 
the corrected final weight of the MPs at equilibrium 
swelling in the medium.
In vitro drug release studies
The drug release studies of the MPs equivalent to 50 
mg of MZ were performed using USP XXIV type I 
dissolution test apparatus (Electrolab, India) at 100 
rpm and 37 ± 0.2 °C in 900 ml simulated GI fluids. 
MPs were filled in hard gelatin capsules and coated 
with optimized eudragit S 100 (5%, four coatings) 
and  then  drug  release  were  studied  in  simulated 
gastric fluid (SGF: HCl/NaCl buffer, pH 1.2) for the 
first 2 hrs. Then, the dissolution medium was replaced 
with simulated intestinal fluid (SIF: KH2PO4/NaOH 
buffer, pH 7.4) and tested for drug release for 3 hrs, 
and finally SCF (KH2PO4/NaOH buffer, pH 6.8) was 
used for 7 hrs to mimic colonic pH conditions. This 
pH status was found upon physiological data (6). 
Periodically samples were withdrawn and replaced 
with  fresh  buffer.  The  withdrawn  samples  were 
filtered and in the filtrate MZ content was measured 
by UV-spectrophotometer (Systronic, Japan) at 302 
nm for pH 1.2 media, and 330 nm for pH 7.4 and 6.8 
media respectively.
In vitro drug release study in the presence of rat 
caecal content (RCC)
The  susceptibility  of  the  pectinate  MPs  to  the 
enzymatic action of colonic bacteria was assessed 
by  continuing  the  drug  release  studies  in  RCC 
medium which was prepared by the reported method 
(6). Phosphate buffer saline (PBS) of pH 6.8, with 
4% w/v RCC was used as SCF. The enteric coated 
capsules filled with 50 mg MZ loaded MPs were 
placed in 200 ml of this dissolution media (PBS, 
pH 6.8). The CO2 was supplied into the dissolution 
medium  during  the  experiment. At  different  time 
intervals, the samples were withdrawn and replaced 
with fresh PBS. The experiment was continued up 
to 24 hrs. The withdrawn samples were centrifuged, 
the  supernatant  was  filtered  and  the  filtrate  was 
analyzed  for  MZ  content  at  330  nm  using  UV-
spectrophotometer (Systronic, Japan).
Fourier transform infrared spectroscopy (FT-IR)
Drug polymer interactions were studied by FT-IR. 
The spectra of different samples were recorded using 
FT-IR  spectrophotometer  (Perkin  Elmer,  Japan). 
Samples were prepared in KBr disks. Each KBr disk 
was scanned over a wave number region of 500 to 
4000 cm-1.
Morphology
The shape and surface morphology of ZPG-MPs and 
CPG-MPs were investigated using scanning electron 
microscopy (SEM). The samples were prepared by 
sprinkling the MPs on a double adhesive tape stuck 
to an aluminum stub. The stubs were then coated 
with gold using a gold sputter module. The coated 
samples were scanned and photomicrographs were 
taken by a scanning electron microscope (Jeol JSM-
1600, Japan).
Radiolabeling of MPs
SnCl2 (3% w/v) loaded ZPG-MPs (200 mg) were 
placed in the test tube and soaked in 10 ml of normal 
saline for 20 min. A small amount of 99mTc solution 
(40 mBq radioactivity) from a Technetium generator 
(column  generator,  Monrol,  Mon-tek,  99Mo99Tc, 
Turkey) was added to test tube. The suspension was 
mixed and MPs were allowed to equilibrate. The 
supernatant was removed and the labeled MPs were 
recovered  by  filtration  followed  by  washing  with 
deionized water and then air dried. Dried MPs were 
filled in gelatin capsules (# 4), and capsules were 
coated  with  optimized  coating  of  eudragit  S100 
polymer (5%, four coatings), and air dried.
Gamma scintigraphy
Six male New Zealand rabbits (3 kg) were used to 
monitor the in vivo transit behavior of ZPG-MPs. 
None of animals had symptoms or a past history 
of GI disease. To standardize the condition of GI 
motility, animals were fasted for 12 hrs prior to the 
experiment. One enteric coated capsule of the ZPG-
MPs was orally administered to each animal by a 
feeding  tube,  followed  by  a  sufficient  volume  of 
drinking water. The location of the formulation in GI 
tract was monitored every one hours by keeping the 
anterior part of subject in front of gamma camera. 
Specific  GI  tract  sites  were  imaged  by  E-Cam 
Single Head gamma camera (Siemen’s, Germany). 
The gamma images were recorded for a 9 hrs study 
period. 
Statistical analysis 
Experimental  data  have  been  represented  as  the 
mean ± s.d. of different independent determinations. 
The data of drug released before entrance in colon 
by ZPG-MPs and CPG-MPs were analysed using 
unpaired  t-test  at  the  significance  level  of  P  < 
0.0001.
RESUlT AND DISCUSSION
Preparation, morphology, size and size distribution
According  to  “Egg-box  model”  (14)  when  the 
MZ  containing  aqueous  dispersion  of  LM-pectin 
was  dropped  into  cross-linking  solutions  (Zn2+  or 
Ca2+  counter-ions),  gelled  spheres  were  produced 
instantaneously.  In  this  process,  intermolecular 
cross-links  were  formed  between  the  negatively 
charged  carboxyl  groups  of  LM-pectin  and 
the  positively  charged  counter-ions.  Various 
formulations  which  were  prepared  are  shown  in 
table 1. SEM photomicrographs showed that ZPG-
MPs  and  CPG-MPs  had  a  spherical  morphology. 
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However, the absence of ideal spherical morphology 
can be probably attributed to the drying process that 
causes  certain  invaginations  in  the  particles.  The 
surface of ZPG-MPs appeared globulous with low 
porosity. As for alginate beads, ZPG-MPs seemed 
to be smaller than CPG-MPs (15) (Figure 1(A) and 
(B)) because calcium ions form loose linkages with 
carboxyl groups in the chains of LM pectin and zinc 
ions form more extensive cross-linking due to its 
mutual interaction. Extensive cross-linking causes 
reduction in size and results are supported by the 
SEM images and optical microscopy. The prepared 
ZPG-MPs  showed  varied  mean  diameter  from 
526.07 ± 6.38 µm to 688.93 ± 4.39 µm. The mean 
diameter  of  CPG-MPs  was  found  723.51  ±  4.53 
µm. The average particle size of all formulations is 
shown in table 2.
Entrapment efficiency, percent yield and swelling ratio
EE,  %  yield  and  SR  of  different  formulation 
batches are presented in table 2. The EE increased 
progressively by increase in polymer concentration 
when prepared at the pH of individual cross-linking 
solution  but  decreased  by  increase  in  pH  of  the 
cross-linking solution from 1.6 to 6.1. As the pH of 
the cross-linking solution was increased, there was 
a decrease in the EE of the respective MPs which 
may be attributed to the reduction in solubility of 
MZ in stronger acid medium, since MZ as a weak 
acid (pKa 5.8) has a negligible solubility in strong 
acid. MZ solubility increased by increase in pH (16). 
The  EE  of  ZPGD2-MPs  and  CPG-MPs  prepared 
under the same conditions were 86.1 ± 1.7 and 83.7 
± 1.3 respectively. The loss of MZ, for ZPG-MPs 
and  CPG-MPs  were  14%  and  17%  respectively, 
whenever determined in the cross-linking solution. 
Higher  loss  for  CPG-MPs  indicates  exclusion  of 
MZ which may be due to the lower degree of cross-
linking and loose matrix structure. 
Swellability  is  an  indicative  parameter  for  rapid 
availability of drug solution for diffusion with greater 
flux. It was found that SR increased by increase in 
polymer concentration owing to rising fluid retained 
capacity. Acidification of cross-linking solution was 
responsible for creation of a strong pectinate counter 
ions network (17). A low pH limited the ionization of 
Formulation Code Particle size (µm) EE (%)b Yield (%)c Swelling ratio at ph 6.8
ZPGA1        4.22 ± 569.34 2.3 ± 81.8 1.4 ± 94.6 0.62 ± 1.87
ZPGA2   7.87 ± 583.18 1.2 ± 82.1 1.3 ± 96.7 0.60 ± 2.68
ZPGB1 5.51 ± 607.58 1.5 ± 74.6 1.6 ± 83.4 0.97 ± 4.79
ZPGB2 6.31 ± 624.63 1.9 ± 75.1 1.9 ± 85.7 1.24 ± 5.22
ZPGC1 3.41 ± 657.79 1.7 ± 69.5 1.7 ± 81.3 1.68 ± 6.12
ZPGC2 4.39 ± 688.93 2.3 ± 71.2 2.6 ± 81.9 1.79 ± 6.83
ZPGD1 3.94 ± 542.32 1.5 ± 84.8 1.1 ± 94.3 0.76 ± 1.49
ZPGD2 6.38 ± 526.07 1.7 ± 86.1 2.1 ± 97.6 0.37 ± 0.88
CPG 4.53 ± 723.51 1.3 ± 83.7 2.5 ± 92.3 1.73 ± 9.17
Table 2. Particles size, entrapment efficiency (EE), % yield and swelling ratio in simulated colonic fluid (pH 6.8) of different formulation 
batchesa.
aResults are mean ± s.d. (n = 3),
bEE (%) = Calculated drug content/Theoretical drug content X 100 
cYield (%) = Total weight of MPs/ total weight of drug and polymer X 100
 Figure 1. Scanning electron microscopy (SEM) of zinc pectinate
 gel microparticles (ZPG-MPs)  (a), and calcium pectinate gel
(microparticles (CPG-MPs) (b
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than CPG-MPs because greater solvent penetration 
was  taken  place  into  the  Ca-pectinate  network. 
ZPGD2 formulation showed highest EE of 86.1 ± 
1.7%, and yield of 97.6 ± 2.1%, smallest particle size 
of 526.07 ± 6.38 µm, and lowest SR 0.88 ± 0.37 and 
spherical in shape thus it was selected as optimized 
formulation for comparative study with CPG-MPs.
Polymer–drug  interaction  analysis  using  FTIR 
spectroscopy
The characteristic IR bands for MZ at 3445 cm-1 were 
observed owing to the mutual overlapping of -NH 
and -OH stretching (Figure 2). The peak at 1653.9 
cm-1 corresponds to the C=O stretching, the peak 
at 1629.4 cm-1 was assigned  to NH (bend), and the 
peaks at 1380.8 cm-1 and 1355.6 cm-1 were attributed 
to  -OH  bending  and  C-N  stretching  respectively. 
The peak at 1452.9 cm-1 showed C=C stretching in 
aromatic compound. The bands in a range of 2000–
3000  cm-1  correspond  to  the  stretching  vibrations 
of the hydrogen bonds in the MZ. The LM-pectin 
showed a broad band between 3500 and 3350 cm-1 
due to OH stretching, a C=O vibration band of COOH 
group at 1734.5 cm-1 and the asymmetric vibration 
stretching of COO− at 1620.5 cm-1. Bands for MZ 
were observed clearly and almost unchanged, in the 
spectrum of D:P physical mixture. Spectra of placebo 
and drug-loaded MPs, showed a strong reduction in 
the LM-pectin band at 1734.5 cm-1, which appeard as 
a shoulder, and a shift to 1638 cm-1 of the carboxylate 
ion vibration stretching band, both indicative of Zn-
pectinate  formation  (18).  On  the  other  hand,  MZ 
characteristic  peaks  were  slightly  reduced  in  the 
spectrum of loaded MPs and appeared at 1568.1, 
1451.7,  1379.5,  1354.6,  772.1,  583.9,  538.5,  and 
482  cm-1  which  suggest  loss  of  drug  crystallinity 
in the MPs and absence of high affinity interaction 
between LM-pectin and MZ in the MPs.
In vitro drug release study
The potential use of MZ loaded ZPG-MPs as CDD 
system was examined by performing the drug release 
study in SGF (pH 1.2 for 2 hrs), SIF (pH 7.4 for 3 
hrs), and SCF (pH 6.8 for 7 hrs) to mimic colonic pH 
conditions. MPs were filled in previously optimized 
eudragit  S  100  coated  hard  gelatin  capsules  then 
tested because the acrylic polymer is not soluble in 
acidic pH (SGF) thus it prevents drug release at pH 
1.2 and starts to dissolve above pH 7. The effect of 
the different factors upon the release and the efficacy 
to target the colon were investigated.
Effect  of  the  pH  of  cross-linking  solutions  and 
concentrations of LM-pectin 
The  effect  of  the  pH  of  cross-linking  solutions 
on the drug release is shown in figure 3(A). The 
MPs prepared in cross-linking solution of pH 1.6 
compared to the MPs prepared at pH 3.8 and 6.1 
showed acceptable slow drug release. These results 
Figure 2. FT-IR spectra of mesalazine (a), low methoxy-pectin 
(b), mesalazine: low methoxy-pectin physical mixture (1:4) (c), 
placebo  zinc  pectinate  gel  microparticles  (d),  and  mesalazine 
loaded zinc pectinate gel microparticles (e).
the LM-pectin by reducing coulombic repulsion and 
favouring a closer gel network. The opposite was 
true at higher pH. Therefore formulation which was 
prepared at low pH (pH 1.6) compared with pH 3.8 
and 6.1 showed small SR values. Cross-linking time 
hardened the formulations and generated stronger 
crosslinks. The SR values of ZPG-MPs were lower 
Kawadkar et al / DARU 2010 18 (3) 211-220216
confirm  that  strong  gel  network  of  pectin  was 
formed at lower pH below 3 (lower than LM-pectin 
intrinsic  pKa  value).  Low  pH  probably  assisted 
intermolecular association by reducing the charges 
on the polymer, thus lowering intermolecular charge–
charge repulsion and also reducing the solubility of 
LM-pectin  chain.  Protonation  of  carboxyl  groups 
appeared  to  promote  conformational  ordering 
and  association  by  suppression  of  electrostatic 
repulsion and allowing the carbonyl groups to act 
as hydrogen-bond donors (19). At pH values where 
most of the carbonyl groups were ionized, the chain 
could be stiffened and extended by intermolecular 
electrostatic repulsion. MZ release with ZPG-MPs 
prepared at pH 3.8 and 6.1was faster than the one 
which was prepared at pH 1.6. The SR values of 
these MPs in SCF (pH 6.8) justify the release study. 
In SGF (pH 1.2) no significant amount of drug was 
released from MPs but 10-15% of the drug was released 
at pH 7.4, which may be due to the diffusion process 
while release in pH 6.8 could follow both diffusion and 
erosion mechanisms. The MZ powder filled capsules 
released entire drug within 2.5 hrs. Figure 3(A) also shows 
the effect of polymer concentration on drug release. 
Increasing the pectin ratio from 2% w/v to 4% w/v 
retarded drug release due to the increase in the density 
Figure 3. Effect of polymer concentration and cross-linking solution pH on drug release from different zinc pectinate gel microparticles in 
simulated GI fluids. Preparation conditions: low methoxy-pectin concentration 2% w/v + cross-linking solution pH 1.6 [■]/3.8 [●]/6.1 [▲], and 
low methoxy-pectin concentration 4% w/v + cross-linking solution pH 1.6 [□]/3.8 [○]/6.1 [∆], Free drug [׀׀] (A). Effect of cross-linking time on 
drug release from different zinc pectinate gel microparticles in simulated GI fluids. Preparation conditions: low methoxy-pectin concentration 
4% w/v + cross-linking solution pH 1.6 + cross-linking time (hrs) 6 [◊]/12 [∆]/24 [□]. Free drug [׀׀] (B).  Values are mean ± s.d. (n = 3).
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of polymer matrix and also an increase in diffusional 
path length that the drug molecules have transverse.
Effect of cross-linking time
The drug release characteristics of the formulations 
ZPGA2,  ZPGD1,  and  ZPGD2  prepared  at  cross-
linking time 6, 12, and 24 hrs respectively in same 
cross-linking  solution  of  pH  1.6  and  drug  filled 
capsule are compared in figure 3 (B). Figure shows 
the order of the release of MZ from formulations 
as: ZPGD2 < ZPGD1 < ZPGA2. ZPGA2, ZPGD1, 
and  ZPGD2  formulations  released  less  than  15% 
up  to  the  end  of  5  hrs  while  drug  filled  capsule 
released entire drug within 2.5 hrs. After 5 hrs, all 
three formulations showed significant difference in 
drug release. It is clear that the drug release from 
the highly cross-linked formulations is slower than 
those of the lower cross-linked formulations. This 
Figure 4. Effect of the type of cross-linking agent on drug release from zinc pectinate gel microparticles and calcium pectinate gel 
microparticles in simulated GI fluids. Preparation conditions: low methoxy-pectin concentration 4% w/v + cross-linking solution of 
pH 1.6 + cross-linking time of 24 hrs + cross-linking agent Zn(CH3COO)2 [○]/CaCl2 [◊], Free drug [׀׀] (A). Effect of rat caecal content 
on drug release from zinc pectinate gel microparticles and calcium pectinate gel microparticles in simulated colonic fluid (pH 6.8). 
Preparation conditions: low methoxy-pectin concentration 4% w/v + cross-linking solution pH 1.6 + cross-linking time 24 hrs + cross-
linking agent Zn(CH3COO)2 [○]/CaCl2 [◊], (B). Values are mean ± s.d. (n = 3).
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is due to the promotion of cross-links between LM-
pectin chains by the Zn (CH3COO)2. The SR values 
at pH 6.8 for ZPGD2, ZPGD1, and ZPGA2 are 0.88 
± 0.32, 2.68 ± 0.28, and 1.49 ± 0.24 respectively and 
these values support the results for drug release. 
Effect of the counter-ion type
The drug release profiles from ZPG-MPs and CPG-
MPs were very different in the intestinal and colonic 
medium.  Figure  4  (A)  shows  that  formulation 
ZPGD2  released  the  drug  in  a  more  controlled 
manner  as  compared  with  formulation  CPG.  The 
release  from  CPG-MPs  became  steady  after  3.25 
hrs which could be due to swelling and hydration of 
MPs by the medium, thus showing its hydrophilic 
nature (12). ZPG-MPs showed slower drug release 
pattern in SIF (pH 7.4) characterized at the end of 
the equilibrium. It is possible that negligible swelling 
Figure 5. Gamma scintigraphic images of mesalazine loaded zinc pectinate gel microparticles in rabbit at different time intervals.
occurred in intestinal medium. Before entrance to 
colon  CPG-MPs  showed  52.73%  of  drug  release 
while ZPG-MPs showed only 7.35%. The statistical 
comparison  of  the  percent  of  drug  released  from 
both formulations before entrance in colon showed 
significant differences (p < 0.0001). The t50%, values 
of CPG-MPs and ZPG-MPs were 4.9 hrs and more 
than  12  hrs  respectively.  These  findings  suggest 
that the Ca2+ ions form loose linkages with carboxyl 
groups in LM-pectin chains compared to Zn2+ ions.
In vitro drug release study in the presence of RCC
To  improve  the  relevance  of  the  findings  on  the 
in  vitro  drug  release  study,  RCC  were  added  in 
dissolution media (20). The in vitro release of MZ 
from  ZPGD2  and  CPG-MPs  in  the  presence  of 
4% w/v RCC in SCF showed faster drug release at 
different time intervals in comparison with release 
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study in the absence of RCC (Figure 4(B)). This 
finding could be attributed to the various anaerobic 
bacteria  present  in  caecal  content  responsible  for 
digestion/degradation of LM-pectin and release of 
the drug from MPs. The t50% value of CPG-MPs was 
3-4 folds greater than ZPG-MPs.
Gamma scintigraphy
Gamma scintigraphy is the most useful technique to 
evaluate in vivo behavior of dosage forms in animals 
and humans since it was first employed to investigate 
in vivo  functionality of tablets and capsules (21). 
The  scintigraphy  of  the  optimized  formulation 
ZPGD2 (92 ± 0.8% Radiolabeling efficiency) filled 
in  enteric  coated  capsule  was  performed  using 
rabbits (animal model) in order to establish its colon 
targeting potential. From the scintigraphic images 
(Figure  5)  it  can  be  interpreted  that  the  capsule 
was completely intact in the stomach up to 2 hrs. 
Images indicate that when capsule containing ZPG-
MPs was in the small intestine the radioactivity was 
concentrated in a very small area indicating that little 
release had occurred. The mean transit time from 
stomach to colon was found to be 6.0±0.47 hrs. The 
capsule started to disintegrate in colon after 6.5 hrs. 
Once the capsule entered the ascending colon, there 
was  considerable  spreading  of  radioactivity  from 
ascending colon toward the transverse colon which 
was most likely caused by the action of the bacterial 
enzymes  in  the  colon  degrading  the  pectin  and 
accelerating the release of radioactivity. Scintigram 
shows the residence of MPs in colon more than 9 
hrs. These results showed that ZPGD2 formulation 
may be useful for targeting MZ to the colon. 
CONClUSION
The  effects  of  different  important  variables  on 
the characteristics of MPs prepared by ionotropic 
gelation  technique  were  examined.  On  the  basis 
of  results,  low  pH  of  the  cross-linking  solution, 
increased cross-linking time and Zn2+ counter-ions 
in  comparison  with  Ca2+  counter-ions  increased 
the strength of the pectinate gel which reduced the 
swelling and drug release. The entrapment of MZ 
(weak  acid),  was  significantly  enhanced  by  the 
drop in pH of the cross-linking solution (maximum 
entrapment at pH 1.6) and also by increase in the 
polymer concentration. Finally, MPs were evaluated 
using enteric coated capsules for the drug release 
under conditions mimicking the overall GI tract (pH 
1.2 then 7.4) and the colon (pH 6.8 with 4% w/v 
RCC). Gamma scintigraphy study of ZPG-MPs using 
enteric coated capsules, demonstrated that ZPG-MPs 
reached the colon with almost all the drug loading 
dose. It is concluded that designed formulation have 
the potential to serve as a colonic delivery system.
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